JP2020520367A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020520367A5 JP2020520367A5 JP2019563540A JP2019563540A JP2020520367A5 JP 2020520367 A5 JP2020520367 A5 JP 2020520367A5 JP 2019563540 A JP2019563540 A JP 2019563540A JP 2019563540 A JP2019563540 A JP 2019563540A JP 2020520367 A5 JP2020520367 A5 JP 2020520367A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- pharmaceutical composition
- subject
- cells
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 163
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 105
- 229920001184 polypeptide Polymers 0.000 claims description 104
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 104
- 206010028980 Neoplasm Diseases 0.000 claims description 83
- 201000011510 cancer Diseases 0.000 claims description 83
- 101150054980 Rhob gene Proteins 0.000 claims description 77
- 102000013446 GTP Phosphohydrolases Human genes 0.000 claims description 62
- 108091006109 GTPases Proteins 0.000 claims description 62
- 239000000126 substance Substances 0.000 claims description 61
- 239000008194 pharmaceutical composition Substances 0.000 claims description 59
- 230000000694 effects Effects 0.000 claims description 54
- 239000002773 nucleotide Substances 0.000 claims description 25
- 125000003729 nucleotide group Chemical group 0.000 claims description 25
- 239000000427 antigen Substances 0.000 claims description 24
- 102000036639 antigens Human genes 0.000 claims description 24
- 108091007433 antigens Proteins 0.000 claims description 24
- 239000002552 dosage form Substances 0.000 claims description 23
- 230000003993 interaction Effects 0.000 claims description 18
- 208000032839 leukemia Diseases 0.000 claims description 11
- 230000004797 therapeutic response Effects 0.000 claims description 10
- 102000054765 polymorphisms of proteins Human genes 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 230000003834 intracellular effect Effects 0.000 claims description 4
- 239000000539 dimer Substances 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 description 175
- 108090000623 proteins and genes Proteins 0.000 description 31
- 108091008874 T cell receptors Proteins 0.000 description 24
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 24
- 239000012634 fragment Substances 0.000 description 21
- 230000035772 mutation Effects 0.000 description 20
- 210000001744 T-lymphocyte Anatomy 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 12
- 230000005934 immune activation Effects 0.000 description 11
- 239000003112 inhibitor Substances 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 10
- 230000001973 epigenetic effect Effects 0.000 description 10
- 230000002068 genetic effect Effects 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- KJTLQQUUPVSXIM-ZCFIWIBFSA-M (R)-mevalonate Chemical compound OCC[C@](O)(C)CC([O-])=O KJTLQQUUPVSXIM-ZCFIWIBFSA-M 0.000 description 9
- KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 description 9
- 230000037361 pathway Effects 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 8
- 210000000170 cell membrane Anatomy 0.000 description 7
- 102000018898 GTPase-Activating Proteins Human genes 0.000 description 6
- 108091006094 GTPase-accelerating proteins Proteins 0.000 description 6
- 108010067218 Guanine Nucleotide Exchange Factors Proteins 0.000 description 6
- 102000016285 Guanine Nucleotide Exchange Factors Human genes 0.000 description 6
- 239000012636 effector Substances 0.000 description 5
- 230000000865 phosphorylative effect Effects 0.000 description 5
- 230000004913 activation Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 150000007523 nucleic acids Chemical group 0.000 description 4
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 4
- 229940046231 pamidronate Drugs 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 4
- 229960004276 zoledronic acid Drugs 0.000 description 4
- 102000008070 Interferon-gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 230000016396 cytokine production Effects 0.000 description 3
- 229960003130 interferon gamma Drugs 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 208000000415 potassium-aggravated myotonia Diseases 0.000 description 2
- 208000004736 B-Cell Leukemia Diseases 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007621 cluster analysis Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- -1 small molecule compound Chemical class 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762508272P | 2017-05-18 | 2017-05-18 | |
| US62/508,272 | 2017-05-18 | ||
| US201762508833P | 2017-05-19 | 2017-05-19 | |
| US62/508,833 | 2017-05-19 | ||
| PCT/EP2018/063210 WO2018211115A1 (en) | 2017-05-18 | 2018-05-18 | Compositions and methods for cell targeting therapies |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2020520367A JP2020520367A (ja) | 2020-07-09 |
| JP2020520367A5 true JP2020520367A5 (enExample) | 2021-07-26 |
| JPWO2018211115A5 JPWO2018211115A5 (enExample) | 2023-04-18 |
| JP7486953B2 JP7486953B2 (ja) | 2024-05-20 |
Family
ID=62492593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019563540A Active JP7486953B2 (ja) | 2017-05-18 | 2018-05-18 | 細胞標的化療法のための組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12161669B2 (enExample) |
| EP (1) | EP3624823A1 (enExample) |
| JP (1) | JP7486953B2 (enExample) |
| CN (1) | CN110944658A (enExample) |
| AU (1) | AU2018268087B2 (enExample) |
| CA (1) | CA3063807A1 (enExample) |
| WO (1) | WO2018211115A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2659217T3 (es) | 2012-03-28 | 2018-03-14 | Gadeta B.V. | Intercambio combinatorio de cadena receptora de célula T gamma 9 delta 2 |
| EP4099015A1 (en) | 2016-06-10 | 2022-12-07 | Gadeta B.V. | Novel method for identifying deltat-cell (or gammat-cell) receptor chains or parts thereof that mediate an anti-tumour or an anti-infective response |
| CA3063807A1 (en) | 2017-05-18 | 2018-11-22 | Umc Utrecht Holding B.V. | Compositions and methods for cell targeting therapies |
| WO2019156566A1 (en) * | 2018-02-12 | 2019-08-15 | Umc Utrecht Holding B.V. | Bispecific molecules comprising gamma-delta tcr and t-cell or nk cell binding domain |
| WO2019219979A1 (en) * | 2018-05-18 | 2019-11-21 | Umc Utrecht Holding B.V. | Compositions and methods for cell targeting therapies |
| EP4267604A1 (en) | 2020-12-23 | 2023-11-01 | Gadeta B.V. | Chimeric, transmembrane proteins with bidirectional signalling activity |
| CN112255395B (zh) * | 2020-12-23 | 2021-06-18 | 中生北控生物科技股份有限公司 | 一种消除脂血样本中乳糜干扰的方法和免疫浊度法试剂盒及应用 |
| JP2024507735A (ja) * | 2021-02-08 | 2024-02-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ブチロフィリンサブファミリー３メンバーａ１（ｂｔｎ３ａ１、ｃｄ２７７）の制御 |
| WO2022214707A1 (en) | 2021-04-09 | 2022-10-13 | Gadeta B.V. | Cellular reporter and methods of using the same |
| WO2023242434A1 (en) | 2022-06-17 | 2023-12-21 | Gadeta B.V. | Modified immune cells |
| GB202406837D0 (en) * | 2024-05-14 | 2024-06-26 | Immunocore Ltd | Screening methods |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5260223A (en) | 1986-07-03 | 1993-11-09 | President & Fellows Of Harvard College | Methods for detection of human gamma, γ T cell receptor |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| EP0557459B1 (en) | 1990-11-13 | 1997-10-22 | Immunex Corporation | Bifunctional selectable fusion genes |
| FR2698880B1 (fr) | 1992-11-25 | 1995-02-24 | Inst Nat Sante Rech Med | Procédé de production de récepteurs T solubles, produits ainsi obtenus et leur utilisation dans des compositions diagnostiques ou thérapeutiques. |
| WO1994028143A1 (en) | 1993-05-21 | 1994-12-08 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US5885827A (en) | 1996-01-23 | 1999-03-23 | The Regents Of The Universtiy Of California | Eukaryotic high rate mutagenesis system |
| US6207455B1 (en) | 1997-05-01 | 2001-03-27 | Lung-Ji Chang | Lentiviral vectors |
| KR100556864B1 (ko) | 1997-05-13 | 2006-03-10 | 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 | 렌티바이러스-기원 유전자 전달 벡터 |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| US6218181B1 (en) | 1998-03-18 | 2001-04-17 | The Salk Institute For Biological Studies | Retroviral packaging cell line |
| GB9810099D0 (en) | 1998-05-11 | 1998-07-08 | Isis Innovation | Novel molecule and diagnostic method |
| DK1066380T3 (da) | 1998-05-19 | 2002-01-28 | Avidex Ltd | Opløselig T-cellereceptor |
| DE19909769A1 (de) | 1999-03-05 | 2000-09-07 | Bundesrepublik Deutschland Let | Von SIVagm abgeleitete lentivirale Vektoren, Verfahren zu ihrer Herstellung und ihre Verwendung zur Genübertragung in Säugerzellen |
| DK1257632T3 (da) | 2000-02-24 | 2008-01-28 | Xcyte Therapies Inc | Samtidig stimulering og opkoncentrering af celler |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| JP2001332430A (ja) | 2000-05-22 | 2001-11-30 | Murata Mfg Co Ltd | トランス |
| AU2001292842A1 (en) | 2000-09-19 | 2002-04-02 | Diadexus, Inc. | Compositions and methods relating to prostate specific genes and proteins |
| KR100669065B1 (ko) | 2001-04-03 | 2007-01-15 | 다카라 바이오 가부시키가이샤 | 세포상해성 ｔ 림프구 |
| US6905827B2 (en) | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
| AU2003235593A1 (en) | 2002-01-10 | 2003-07-30 | National Jewish Medical And Research Center | USE OF SOLUBLE GammaDelta T CELL RECEPTORS FOR REGULATING T CELL FUNCTION |
| MXPA05001933A (es) | 2002-08-19 | 2005-04-28 | Genentech Inc | Composiciones y metodos para el diagnostico y tratamiento de tumores. |
| US7569664B2 (en) | 2002-10-09 | 2009-08-04 | Immunocore Limited | Single chain recombinant T cell receptors |
| US7892745B2 (en) | 2003-04-24 | 2011-02-22 | Xdx, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
| US7601801B2 (en) | 2003-07-11 | 2009-10-13 | Dainippon Sumitomo Pharma Co., Ltd. | HLA-A24 binding cancer antigen peptide derived from livin |
| WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| JP5563194B2 (ja) | 2004-06-29 | 2014-07-30 | イムノコア リミテッド | 改変ｔ細胞レセプターを発現する細胞 |
| GB0425732D0 (en) * | 2004-11-23 | 2004-12-22 | Avidex Ltd | Gamma-delta t cell receptors |
| GB0506760D0 (en) | 2005-04-01 | 2005-05-11 | Avidex Ltd | High affinity HIV TCRS |
| CA2618580A1 (en) | 2005-08-08 | 2007-02-15 | Fondazione Centro San Raffaele Del Monte Tabor | Use of common .gamma. chain cytokines for the visualization, isolation and genetic modification of memory t lymphocytes |
| US20080131415A1 (en) | 2006-11-30 | 2008-06-05 | Riddell Stanley R | Adoptive transfer of cd8 + t cell clones derived from central memory cells |
| JP2010520748A (ja) | 2007-02-20 | 2010-06-17 | アナプティスバイオ インコーポレイティッド | 体細胞超変異系 |
| ES2622505T3 (es) | 2008-05-09 | 2017-07-06 | Agency For Science, Technology And Research | Receptor de linfocito T (RLT) exógeno reactivo contra epítopo de VHB y usos del mismo |
| CA2743669C (en) | 2008-11-24 | 2018-10-16 | Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) | High affinity t cell receptor and use thereof |
| WO2010087335A1 (ja) | 2009-01-27 | 2010-08-05 | 学校法人産業医科大学 | Ｔ細胞抗原受容体遺伝子、受容体α鎖及びβ鎖発現用ベクター並びに細胞障害性Ｔ細胞 |
| EP3970736A1 (en) | 2009-11-02 | 2022-03-23 | Emory University | Drug resistant immunotherapy for treatment of a cancer |
| CN102453701B (zh) | 2010-10-26 | 2014-08-13 | 中国医学科学院基础医学研究所 | 基因修饰CDR3δ移植型γδT淋巴细胞及其抑癌用途 |
| US20150353643A1 (en) * | 2013-09-24 | 2015-12-10 | Universite De La Mediterranee - Aix-Marseille Ii | Anti-cd277 antibodies and uses thereof |
| EP2686417B1 (de) | 2011-03-17 | 2016-06-08 | Miltenyi Biotec GmbH | Tcralpha/beta-depletierte zellpräparationen |
| CN102532269B (zh) | 2011-05-16 | 2014-07-09 | 中国医学科学院基础医学研究所 | γδT淋巴细胞中δ1链互补决定域3的优势序列及其TCR受体转染细胞与应用 |
| WO2012156958A2 (en) | 2011-05-19 | 2012-11-22 | Instituto De Medicina Molecular | Cell line of lymphocytes comprising gamma-delta t cells, composition and production method thereof |
| PE20141520A1 (es) | 2011-07-29 | 2014-11-17 | Univ Pennsylvania | Receptores coestimuladores de cambio |
| ES2659217T3 (es) | 2012-03-28 | 2018-03-14 | Gadeta B.V. | Intercambio combinatorio de cadena receptora de célula T gamma 9 delta 2 |
| ES2824024T3 (es) | 2012-10-10 | 2021-05-11 | Sangamo Therapeutics Inc | Compuestos modificadores de células T y usos de los mismos |
| EP2916858A1 (en) * | 2012-11-08 | 2015-09-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for inducing il-2-free proliferation of gamma delta t cells |
| US20160091491A1 (en) | 2013-05-02 | 2016-03-31 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for diagnosis of celiac disease |
| WO2015063069A1 (en) | 2013-10-28 | 2015-05-07 | Benjamin Felder | Chimeric antigen receptors with antigen binding domains derived from gamma delta t cell receptors |
| CN106103711A (zh) | 2013-11-21 | 2016-11-09 | 组库创世纪株式会社 | T细胞受体和b细胞受体库分析系统及其在治疗和诊断中的应用 |
| PT3102609T (pt) | 2014-02-04 | 2024-10-23 | Us Health | Métodos de produção de células t autólogas úteis para o tratamento de malignidades das células b e de outros cancros e respetivas composições |
| US11505605B2 (en) | 2014-05-13 | 2022-11-22 | Chugai Seiyaku Kabushiki Kaisha | T cell-redirected antigen-binding molecule for cells having immunosuppression function |
| GB201506423D0 (en) * | 2015-04-15 | 2015-05-27 | Tc Biopharm Ltd | Gamma delta T cells and uses thereof |
| JP6685047B2 (ja) * | 2015-02-02 | 2020-04-22 | 国立大学法人 長崎大学 | 新規フッ素含有型ビスホスホン酸誘導体及びその用途 |
| WO2016195086A1 (ja) | 2015-06-05 | 2016-12-08 | 医療法人社団 滉志会 | アレルギー性疾患の治療薬 |
| AU2016301970A1 (en) | 2015-08-06 | 2018-03-22 | Agency For Science, Technology And Research | IL2Rbeta/common gamma chain antibodies |
| MA44907A (fr) | 2015-09-11 | 2018-07-18 | Agenus Inc | Cellules hôtes génétiquement modifiées et leurs procédés d'utilisation |
| CN105296431B (zh) | 2015-11-26 | 2018-10-09 | 北京佳德和细胞治疗技术有限公司 | 肿瘤结合特异性γδTCR基因修饰的αβT细胞及其抑癌用途 |
| WO2017096239A1 (en) | 2015-12-04 | 2017-06-08 | St. Jude Children's Research Hospital, Inc. | Cloning and expression system for t-cell receptors |
| JP7210286B2 (ja) | 2016-05-12 | 2023-01-23 | アディセット バイオ， インコーポレイテッド | γδＴ細胞集団の選択的増殖方法及びその組成物 |
| EP4099015A1 (en) | 2016-06-10 | 2022-12-07 | Gadeta B.V. | Novel method for identifying deltat-cell (or gammat-cell) receptor chains or parts thereof that mediate an anti-tumour or an anti-infective response |
| WO2018162563A1 (en) | 2017-03-07 | 2018-09-13 | Universität Basel | Mr1 restricted t cell receptors for cancer immunotherapy |
| CA3063807A1 (en) | 2017-05-18 | 2018-11-22 | Umc Utrecht Holding B.V. | Compositions and methods for cell targeting therapies |
| WO2019156566A1 (en) | 2018-02-12 | 2019-08-15 | Umc Utrecht Holding B.V. | Bispecific molecules comprising gamma-delta tcr and t-cell or nk cell binding domain |
| WO2019219979A1 (en) | 2018-05-18 | 2019-11-21 | Umc Utrecht Holding B.V. | Compositions and methods for cell targeting therapies |
-
2018
- 2018-05-18 CA CA3063807A patent/CA3063807A1/en active Pending
- 2018-05-18 AU AU2018268087A patent/AU2018268087B2/en not_active Ceased
- 2018-05-18 US US16/614,691 patent/US12161669B2/en active Active
- 2018-05-18 CN CN201880048211.9A patent/CN110944658A/zh active Pending
- 2018-05-18 EP EP18728543.2A patent/EP3624823A1/en active Pending
- 2018-05-18 WO PCT/EP2018/063210 patent/WO2018211115A1/en not_active Ceased
- 2018-05-18 JP JP2019563540A patent/JP7486953B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020520367A5 (enExample) | ||
| JP7408534B2 (ja) | 分子機能プロファイルを生成、視覚化、及び分類するためのシステム及び方法 | |
| Zhou et al. | Single-cell CRISPR screens in vivo map T cell fate regulomes in cancer | |
| Smith et al. | Drivers of heterogeneity in synovial fibroblasts in rheumatoid arthritis | |
| US7198895B2 (en) | In vitro cell-based methods for biological validation and pharmacological screening of chemical entities and biologicals | |
| Sugimoto et al. | The galanin signaling cascade is a candidate pathway regulating oncogenesis in human squamous cell carcinoma | |
| AU2016281772B2 (en) | Detection of chromosome interactions | |
| Milano et al. | Molecular subsets in the gene expression signatures of scleroderma skin | |
| Julià et al. | An eight-gene blood expression profile predicts the response to infliximab in rheumatoid arthritis | |
| JP2006507794A5 (enExample) | ||
| CN114556480A (zh) | 肿瘤微环境的分类 | |
| Goswami et al. | Myeloid-specific KDM6B inhibition sensitizes glioblastoma to PD1 blockade | |
| FI3774897T3 (fi) | Menetelmiä ja järjestelmiä tulehdustautisten potilaiden valintaan ja hoitoon | |
| US20200109455A1 (en) | Systems and methods for predicting clinical responses to immunotherapies | |
| KR20180028524A (ko) | Fgfr 발현 및 fgfr 억제제에 대한 민감성 | |
| WO2019135957A1 (en) | Immune gene expression signature in treg enriched tumor samples | |
| JP2020515236A5 (enExample) | ||
| Miller et al. | Programs, origins, and niches of immunomodulatory myeloid cells in gliomas | |
| US20230085358A1 (en) | Methods for cancer tissue stratification | |
| Leppä et al. | Single-cell multiomics analysis reveals dynamic clonal evolution and targetable phenotypes in acute myeloid leukemia with complex karyotype | |
| WO2023092119A2 (en) | Methods for predicting responsiveness to a cancer therapy | |
| Smith et al. | Heterogeneity of inflammation-associated synovial fibroblasts in rheumatoid arthritis and its drivers | |
| US20220296642A1 (en) | Methods of Making Therapeutic T Lymphocytes | |
| WO2017218757A1 (en) | Methods and materials for treating cancer | |
| Xu et al. | An image-based transcriptomics atlas reveals the regional and microbiota-dependent molecular, cellular, and spatial structure of the murine gut |